Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Second-generation antipsychotics (SGAPs) and second-generation antidepressants (SGADs) have multiple US Food and Drug Administration-approved indications and are frequently prescribed by primary care physicians. We review the relative potential of these drugs to cause weight gain and glucose dysregulation, and offer clinical guidance to minimize and manage this risk. Among SGAPs, clozapine and olanzapine have a high risk for causing weight gain and glucose dysregulation; iloperidone, paliperidone, quetiapine, and risperidone have a medium risk; and aripiprazole, asenapine, lurasidone, and ziprasidone have a low risk. Young, drug-naïve patients are particularly vulnerable to weight gain associated with SGAPs. With the exception of clozapine, SGAPs have modest differences in their efficacy; however, their side effect profiles may influence selection. Using SGAPs with high metabolic liability conservatively and limiting their off-label use are important means to minimize risk. Patients should be screened before initiating any SGAP (or any antipsychotic medication) and monitored subsequently following standard guidelines, such as those provided by the American Diabetes Association. Healthy lifestyle counseling should be offered to all patients. Patients showing evidence of significant weight gain should be switched to an SGAP with a lower metabolic liability. Metformin may have some utility in young patients with limited exposure to antipsychotic drugs if lifestyle interventions fail and switching the SGAP is not an option. This option should be tried sooner than later for the best possible result. For SGADs, paroxetine and mirtazapine are associated with weight gain, and bupropion may cause modest weight loss. Other SGADs are mostly weight neutral, but individual variations may occur. Depression is associated with weight change and is a risk factor for glucose dysregulation. Treatment of depression improves glucose metabolism. We recommend that all patients taking SGADs be screened using anthropometric measures and metabolic assessment at baseline. Monitoring should be guided individually based on weight gain and other risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Zimmet, P., Alberti, K. G. M. M., & Serrano Ríos, M. (2005) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60742-1 · Cited by 864
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 1×
“com There has been a dramatic increase in the use of anti psychotic (AP) and antidepressant (AD) medications over the past decade.(3,4) Both are frequently prescribed by primary care physicians (PCPs).”
BackgroundAntidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · cited 1×
“Young patients with no prior exposure to APs are particularly vulnerable to weight gain and other metabolic complications.(14) Based on data from 34 head-to-head and placebo-controlled studies of 4 to 52 weeks’ (mostly 6–12 weeks) duration in young patients with psychotic and bipolar disorders, Maayan and Correll(17)…”
BackgroundThe Pharmacologic Management of SSRI-Induced Side Effects: A Survey of Psychiatrists
Dording, C., Mischoulon, D., Petersen, T., Kornbluh, R., Gordon, J., Nierenberg, A., Rosenbaum, J., & Fava, M. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147450 · Cited by 109 · cited 1×
“systematically studied, but a switching strategy is frequently used to address this and other side effects.(92)”
Method
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“among antipsychotics, that has been confirmed in different studies and meta-analyses (11,23-33).”
BackgroundResultInfluentialObesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State
Savini, I., Catani, M., Evangelista, D., Gasperi, V., & Avigliano, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510497 · Cited by 503
Obesity and cognitive decline: role of inflammation and vascular changes
Nguyen, J. C. D., Killcross, A. S., & Jenkins, T. A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00375 · Cited by 425
Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288
Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis
Brownley, K. A., Berkman, N. D., Peat, C. M., Lohr, K. N., Cullen, K. E., Bann, C. M., & Bulik, C. M. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2455 · Cited by 285
Metadata
- Authors
- Hasnain, M., Vieweg, W. V. R., & Hollett, B.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 124
- Issue
- 4
- Pages
- 154-167
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2022018004
- Cited by
- 93
- References
- 11
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians. https://app.cochat.ai/papers/10.3810/pgm.2012.07.2577
- The paper
- Hasnain, M., Vieweg, W. V. R., & Hollett, B. (2012). Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants: A Review for Primary Care Physicians. Postgraduate Medicine. https://doi.org/10.3810/pgm.2012.07.2577
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.